TY - JOUR AU - Claxton, K. P. AU - Sculpher, M. J. AU - Drummond, M. F. PY - 2002 DA - 2002// TI - A Rational Framework for Decision Making by the National Institute for Clinical Excellence (NICE) JO - The Lancet VL - 360 UR - https://doi.org/10.1016/S0140-6736(02)09832-X DO - 10.1016/S0140-6736(02)09832-X ID - Claxton2002 ER - TY - BOOK AU - Drummond, M. F. AU - Sculpher, M. J. AU - Torrance, G. W. AU - O'Brien, B. J. AU - Stoddart, G. L. PY - 2006 DA - 2006// TI - Methods for the Economic Evaluation of Health Care Programmes PB - Oxford University Press CY - Oxford ID - Drummond2006 ER - TY - CHAP AU - Fenwick, E. AU - Claxton, K. P. AU - Sculpher, M. J. AU - Briggs, A. PY - 2000 DA - 2000// TI - Improving the Efficiency and Relevance of Health Technology Assessment: the Role of Iterative Decision Analytic Modelling BT - Technical Report 179 PB - Centre for Health Economics, University of York CY - UK ID - Fenwick2000 ER - TY - BOOK AU - Spiegelhalter, D. J. AU - Abrams, K. R. AU - Myles, J. P. PY - 2004 DA - 2004// TI - Bayesian Approaches to Clinical Trials and Health-Care Evaluation PB - Sons Ltd CY - Chichester ID - Spiegelhalter2004 ER - TY - JOUR AU - Griffin, S. C. AU - Claxton, K. P. AU - Palmer, S. J. AU - Sculpher, M. J. PY - 2011 DA - 2011// TI - Dangerous Omissions: The Consequences of Ignoring Decision Uncertainty JO - Health Econ VL - 20 UR - https://doi.org/10.1002/hec.1586 DO - 10.1002/hec.1586 ID - Griffin2011 ER - TY - JOUR AU - Ioannidis, J. P. PY - 2007 DA - 2007// TI - Is molecular profiling ready for use in clinical decision making? JO - The Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-3-301 DO - 10.1634/theoncologist.12-3-301 ID - Ioannidis2007 ER - TY - CHAP AU - Buxton, M. J. ED - Drummond, M. F. PY - 1987 DA - 1987// TI - Problems in the economic appraisal of new health technology: The evaluation of heart transplants in the UK BT - Economic appraisal of health technology in the European Community PB - Oxford Medical Publications CY - Oxford ID - Buxton1987 ER - TY - JOUR AU - Van 't Veer, L. J. AU - Dai, H. AU - Van de Vijver, M. J. PY - 2002 DA - 2002// TI - Gene expression profiling predicts clinical outcome of breast cancer JO - Nature VL - 415 UR - https://doi.org/10.1038/415530a DO - 10.1038/415530a ID - Van 't Veer2002 ER - TY - JOUR AU - Van de Vijver, M. J. AU - He, Y. D. AU - van 't Veer, L. J. PY - 2002 DA - 2002// TI - A Gene-Expression Signature as a Predictor of Survival in Breast Cancer JO - N Engl J Med VL - 347 UR - https://doi.org/10.1056/NEJMoa021967 DO - 10.1056/NEJMoa021967 ID - Van de Vijver2002 ER - TY - JOUR AU - Buyse, M. AU - Loi, S. AU - van't Veer, L. PY - 2006 DA - 2006// TI - Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer JO - J Natl Cancer Inst VL - 98 UR - https://doi.org/10.1093/jnci/djj329 DO - 10.1093/jnci/djj329 ID - Buyse2006 ER - TY - JOUR AU - Bueno-de-Mesquita, J. M. AU - Linn, S. C. AU - Keijzer, R. PY - 2009 DA - 2009// TI - Validation of 70-gene prognosis signature in node-negative breast cancer JO - Breast Cancer Res Treat VL - 117 UR - https://doi.org/10.1007/s10549-008-0191-2 DO - 10.1007/s10549-008-0191-2 ID - Bueno-de-Mesquita2009 ER - TY - JOUR AU - Bueno-de-Mesquita, J. M. AU - van Harten, W. AU - Retèl, V. PY - 2007 DA - 2007// TI - Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) JO - Lancet Oncol VL - 8 UR - https://doi.org/10.1016/S1470-2045(07)70346-7 DO - 10.1016/S1470-2045(07)70346-7 ID - Bueno-de-Mesquita2007 ER - TY - JOUR AU - Cardoso, F. AU - Van't Veer, L. AU - Rutgers, E. PY - 2008 DA - 2008// TI - Clinical application of the 70-gene profile: the MINDACT trial JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.3222 DO - 10.1200/JCO.2007.14.3222 ID - Cardoso2008 ER - TY - JOUR AU - Ramsey, S. D. AU - Veenstra, D. AU - Tunis, S. R. PY - 2011 DA - 2011// TI - How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment JO - Health Aff (Millwood) VL - 30 UR - https://doi.org/10.1377/hlthaff.2010.0637 DO - 10.1377/hlthaff.2010.0637 ID - Ramsey2011 ER - TY - JOUR AU - Douma, K. F. AU - Karsenberg, K. AU - Hummel, M. J. PY - 2007 DA - 2007// TI - Methodology of constructive technology assessment in health care JO - Int J Technol Assess Health Care VL - 23 UR - https://doi.org/10.1017/S0266462307070262 DO - 10.1017/S0266462307070262 ID - Douma2007 ER - TY - JOUR AU - Schot, J. W. PY - 1992 DA - 1992// TI - Constructive Technology assessment and Technology Dynamics: The Case of Clean Technologies JO - Science, Technology & Human Values VL - 17 UR - https://doi.org/10.1177/016224399201700103 DO - 10.1177/016224399201700103 ID - Schot1992 ER - TY - JOUR AU - Schot, J. AU - Rip, A. PY - 1996 DA - 1996// TI - The Past and Future of Constructive Technology Assessment JO - Technological Forecasting and Social Change VL - 54 UR - https://doi.org/10.1016/S0040-1625(96)00180-1 DO - 10.1016/S0040-1625(96)00180-1 ID - Schot1996 ER - TY - JOUR AU - Ploem, M. C. AU - Retèl, V. P. AU - Linn, S. C. PY - 2010 DA - 2010// TI - Tumour tissue: who is in control? JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70318-3 DO - 10.1016/S1470-2045(09)70318-3 ID - Ploem2010 ER - TY - JOUR AU - Retèl, V. P. AU - Bueno-de-Mesquita, J. M. AU - Hummel, M. J. PY - 2009 DA - 2009// TI - Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics JO - Int J Technol Assess Health Care VL - 25 UR - https://doi.org/10.1017/S0266462309090102 DO - 10.1017/S0266462309090102 ID - Retèl2009 ER - TY - JOUR AU - Retèl, V. P. AU - Joore, M. A. AU - Knauer, M. PY - 2010 DA - 2010// TI - Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2010.02.035 DO - 10.1016/j.ejca.2010.02.035 ID - Retèl2010 ER - TY - JOUR AU - Goldhirsch, A. AU - Wood, W. C. AU - Gelber, R. D. PY - 2007 DA - 2007// TI - Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 JO - Ann Oncol VL - 18 UR - https://doi.org/10.1093/annonc/mdm271 DO - 10.1093/annonc/mdm271 ID - Goldhirsch2007 ER - TY - JOUR AU - Ravdin, P. M. AU - Siminoff, L. A. AU - Davis, G. J. PY - 2001 DA - 2001// TI - Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer JO - J Clin Oncol VL - 19 ID - Ravdin2001 ER - TY - JOUR AU - Kuntz, K. M. AU - Tsevat, J. AU - Weinstein, M. C. PY - 1999 DA - 1999// TI - Expert panel vs decision-analysis recommendations for post discharge coronary angiography after myocardial infarction JO - JAMA VL - 282 UR - https://doi.org/10.1001/jama.282.23.2246 DO - 10.1001/jama.282.23.2246 ID - Kuntz1999 ER - TY - JOUR AU - Ramwadhdoebe, S. AU - Van Merode, G. G. AU - Boere-Boonekamp, M. M. PY - 2010 DA - 2010// TI - Implementation by simulation; strategies for ultrasound screening for hip dysplasia in the Netherlands JO - BMC Health Serv Res VL - 10 UR - https://doi.org/10.1186/1472-6963-10-75 DO - 10.1186/1472-6963-10-75 ID - Ramwadhdoebe2010 ER - TY - JOUR AU - Garrison, L. P. AU - Veenstra, D. L. PY - 2009 DA - 2009// TI - The Economic Value of Innovative Treatments over the Product Life Cycle: the case of Targeted Trastuzumab Therapy for Breast Cancer JO - Value Health VL - 12 UR - https://doi.org/10.1111/j.1524-4733.2009.00572.x DO - 10.1111/j.1524-4733.2009.00572.x ID - Garrison2009 ER - TY - BOOK AU - Rogers, E. M. PY - 2003 DA - 2003// TI - Diffusion of Innovations PB - Free Press CY - New York ID - Rogers2003 ER - TY - JOUR AU - Rutgers, E. AU - Piccart-Gebhart, M. J. AU - Bogaerts, J. PY - 2011 DA - 2011// TI - The EORTC 10041/BIG 03–04 MINDACT trial is feasible: results of the pilot phase JO - Eur J Cancer VL - 47 UR - https://doi.org/10.1016/j.ejca.2011.09.016 DO - 10.1016/j.ejca.2011.09.016 ID - Rutgers2011 ER - TY - STD TI - Royal Dutch Shell Company: . 2010, 7: 6-20. Available at: http://www.shell.com/home/content/aboutshell/our_strategy/shell_global_scenarios/dir_global_scenarios_07112006.html UR - http://www.shell.com/home/content/aboutshell/our_strategy/shell_global_scenarios/dir_global_scenarios_07112006.html ID - ref28 ER - TY - JOUR AU - Wack, P. PY - 1985 DA - 1985// TI - Scenarios: uncharted waters ahead JO - Harvard Business Review VL - 63 ID - Wack1985 ER - TY - JOUR AU - Wack, P. PY - 1985 DA - 1985// TI - Scenarios: shooting the rapids JO - Harvard Business Review VL - 63 ID - Wack1985 ER - TY - BOOK AU - Oostenbrink, J. B. AU - Koopmanschap, M. A. AU - Rutten, F. F. H. PY - 2006 DA - 2006// TI - Manual for cost analyses, methods and standard prices for economic evaluations in health care PB - Dutch Health Insurance Executive Board CY - Amstelveen (The Netherlands) ID - Oostenbrink2006 ER - TY - JOUR AU - Buxton, M. J. PY - 2006 DA - 2006// TI - Economic Evaluation and Decision Making in the UK JO - Pharmacoeconomics VL - 24 UR - https://doi.org/10.2165/00019053-200624110-00009 DO - 10.2165/00019053-200624110-00009 ID - Buxton2006 ER - TY - JOUR AU - Lothgren, M. AU - Zethraeus, N. PY - 2000 DA - 2000// TI - Definition, interpretation and calculation of cost-effectiveness acceptability curves JO - Health Econ VL - 9 UR - https://doi.org/3.0.CO;2-V DO - 3.0.CO;2-V ID - Lothgren2000 ER - TY - JOUR AU - Fenwick, E. AU - Claxton, K. AU - Sculpher, M. PY - 2001 DA - 2001// TI - Representing uncertainty: the role of cost-effectiveness acceptability curves JO - Health Econ VL - 10 UR - https://doi.org/10.1002/hec.635 DO - 10.1002/hec.635 ID - Fenwick2001 ER - TY - JOUR AU - Grutters, J. P. AU - Seferina, S. C. AU - Tjan-Heijnen, V. C. PY - 2011 DA - 2011// TI - Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions JO - Value Health VL - 14 UR - https://doi.org/10.1016/j.jval.2011.01.005 DO - 10.1016/j.jval.2011.01.005 ID - Grutters2011 ER - TY - JOUR AU - Vallejo-Torres, L. AU - Steuten, L. M. AU - Buxton, M. J. PY - 2008 DA - 2008// TI - Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach JO - Int J Technol Assess Health Care VL - 24 UR - https://doi.org/10.1017/S0266462308080604 DO - 10.1017/S0266462308080604 ID - Vallejo-Torres2008 ER - TY - STD TI - Retèl VP, Grutters JPC, van Harten WH, Joore MA: Value of research and value of development in early stages of development of new medical technologies. , Dissertation, available at: http://doc.utwente.nl/78236/ UR - http://doc.utwente.nl/78236/ ID - ref37 ER - TY - JOUR AU - Goldhirsch, A. AU - Ingle, J. N. AU - Gelber, R. D. PY - 2009 DA - 2009// TI - Threshold for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 JO - Ann Oncol VL - 20 UR - https://doi.org/10.1093/annonc/mdp322 DO - 10.1093/annonc/mdp322 ID - Goldhirsch2009 ER - TY - JOUR AU - Bojke, L. AU - Claxton, K. AU - Bravo-Vergel, Y. PY - 2010 DA - 2010// TI - Eliciting distributions to populate decision analytic models JO - Value Health VL - 13 UR - https://doi.org/10.1111/j.1524-4733.2010.00709.x DO - 10.1111/j.1524-4733.2010.00709.x ID - Bojke2010 ER - TY - JOUR AU - Lin, C. AU - Buxton, M. B. AU - Moore, D. PY - 2012 DA - 2012// TI - Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) JO - Breast Cancer Res Treat VL - 132 UR - https://doi.org/10.1007/s10549-011-1670-4 DO - 10.1007/s10549-011-1670-4 ID - Lin2012 ER -